Clinical Studies

Current Clinical Study

Now recruiting Canadian subjects & clinical sites for our Contino® Post Market Clinical Follow-up study.

The Contino® urethral insert is a non-surgical self-administered licensed medical device that controls bladder leakage in men. In the June 2020 edition of the Canadian Urology Association Journal (CUAJ) Contino® foundational clinical study was published.

We are now enrolling male volunteers with urinary incontinence to participate in a post-market clinical follow-up study for the medical device.

If eligible to participate, you will be seen by a study doctor and will receive study-related testing and the medical device at no cost. If enrolled, you may be reimbursed for parking and travel expenses.

You may be eligible if:

you are male, 18 years of age or older; and
you have evidence of moderate to severe urinary incontinence

There will be six visits to the study doctor’s office over the course of one year.

To see if you are an eligible candidate, complete this questionnaire or visit myconti.no/study.

You may also contact the CMX Research Patient Recruitment Centre at 1 (866) 666-3329 or by email at trials@cmxres.com

The foundational study for Contino® was published in the June 2020 edition of the Canadian Urology Association Journal (CUAJ). The five-year multi-site study demonstrated safety and efficacy of improved management of stress urinary incontinence in men. Study participants experienced medically and statistically significant reduction in absorbent pad weight and improved in quality of life. In addition, some participants observed urinary system improvements including improved urge reflex and bladder sensitivity. It is important to note there were no serious adverse events (AE) reported and of the non-serious AE reported, virtually all were minor, expected and resolved with no medical intervention. To learn about Contino®, visit mycontino.com.

Click below to access the CUAJ abstract included on page S59.

Foundational Study